Saxenda vs Zepbound for weight loss

On the numbers that decide most choices, Zepbound leads. On its label, adults without diabetes on Zepbound 15 mg lost an average 20.9% of body weight over 72 weeks, against 3.1% on placebo (Zepbound prescribing information). On the Saxenda label, adults without diabetes on liraglutide 3 mg lost 7.4% over 56 weeks, against 3.0% (Saxenda prescribing information).

No large trial has tested zepbound vs saxenda head to head, so read the gap as a direction. Zepbound also takes one injection a week rather than seven. The FDA approval of Zepbound came in November 2023, for adults with obesity or with overweight and a related condition. Saxenda keeps two real advantages: approval for teens 12 and older, and a weight-management record going back to 2014.

FDA's drug shortage data now list brand Saxenda as to be discontinued, with supply available until January 2027 (FDA drug shortage data). On the weekly side, Harbor offers compounded tirzepatide, which is not FDA approved and is not Zepbound.

The table sets out liraglutide vs tirzepatide from each FDA label and dated price data. Saxenda and Victoza are the same molecule at different doses, as the Saxenda vs Victoza explained guide shows. Only the Saxenda dose is approved for weight, so the liraglutide vs zepbound rows use Saxenda and its generics.

Scroll the table sideways to see both columns →

Saxenda vs zepbound comes down to one receptor or two, a daily or weekly routine, and results of very different size. For liraglutide on its own, see the Saxenda dosing & uses guide.

How each medication works

Liraglutide is a GLP-1 receptor agonist, a modified form of the gut hormone GLP-1 that shares 97% of its amino acid sequence. Its half-life is about 13 hours, which is why Saxenda is injected every day.

Tirzepatide activates two receptors, GIP and GLP-1. A fatty acid chain binds it to albumin in the blood, stretching its half-life to about 5 to 6 days. That is the saxenda vs tirzepatide difference: one hormone pathway against two.

Weight loss results in trials

Saxenda's main label trial enrolled 3,731 adults without diabetes. After 56 weeks, 62.3% of people on liraglutide 3 mg had lost at least 5% of their weight and 33.9% more than 10%, against 34.4% and 15.4% on placebo. The published paper, using a different analysis, reported an average loss of 8.4 kg against 2.8 kg (NEJM, 2015).

SURMOUNT-1, Zepbound's main trial, enrolled 2,539 adults without diabetes for 72 weeks (NEJM, 2022). On the label, average weight change was 15.0%, 19.5% and 20.9% on the 5, 10 and 15 mg doses, against 3.1% on placebo. At 15 mg, 56.7% of people lost at least 20% of their weight.

In adults with type 2 diabetes, the labels show the same order: 5.4% on Saxenda against 1.7%, and 14.7% on Zepbound 15 mg against 3.2%. The trials differ in length and design. The comparison is indirect.

Saxenda dosing vs Zepbound dosing

Saxenda dosing starts at 0.6 mg a day for one week and rises by 0.6 mg each week to 3 mg in week 5. For adults, 3 mg is the treatment dose and the lower steps are titration only. The label also sets a check for adults at 16 weeks: if you have not lost at least 4% of your starting weight, it says to stop Saxenda.

Zepbound dosing starts at 2.5 mg once a week for 4 weeks. It then rises in 2.5 mg steps, at least 4 weeks apart, to a maintenance dose of 5, 10 or 15 mg. Both are injected under the skin at any time, with or without meals.

Missed doses work differently. On Saxenda, a gap of more than 3 days means restarting at 0.6 mg and climbing again. On Zepbound, a missed dose can still be given within 4 days. With compounded tirzepatide, a licensed clinician sets the dose and schedule.

Cost & coverage

The saxenda cost question starts with wholesale prices. The ADA's 2026 Standards of Care put the median 30-day wholesale price of liraglutide 3 mg at $1,619 and of tirzepatide pens at $1,304, as of July 2025, before any coverage or discount (ADA, 2026).

Cash programs moved the Zepbound number. In February 2026, the Zepbound KwikPen launched on the maker's direct site from $299 a month at the lowest dose (CNBC). The White House had announced in November 2025 that Zepbound would average $346 a month through TrumpRx (White House, 2025). Coverage varies by plan for both.

Generic liraglutide for weight management has been FDA approved since August 2025 (generic liraglutide label), though the ADA table lists no generic price. Compounded tirzepatide through Harbor is listed at $149 a month, flat as the dose rises. It is not FDA approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients (FDA).

Harbor compounded tirzepatide is a once-weekly injection at one flat monthly price. A board-certified physician reviews your health history and goals before deciding whether it is appropriate. If it is not the right fit, you are not charged.

Weekly tirzepatide may suit you when:

• Average result size matters most to you
• A weekly injection suits you better than a daily one
• You want a monthly price that does not rise with your dose
• You have obstructive sleep apnea with obesity, which Zepbound is approved to treat

Daily liraglutide may suit you when:

• The patient is a teen aged 12 or older, since Zepbound is for adults only
• Your plan covers generic liraglutide for weight

Anyone weighing saxenda vs mounjaro compares the same two molecules. Mounjaro is tirzepatide approved for type 2 diabetes in adults and children 10 and older, and to lower major cardiovascular risk in high-risk adults with type 2 diabetes. Weight management is Zepbound's label, not Mounjaro's (Mounjaro prescribing information).

FDA declared the tirzepatide shortage resolved in December 2024, and its grace period for pharmacies has ended. Compounding now runs on individual prescriptions from licensed pharmacies (FDA). Every trial result here comes from the brand products.

On weight loss, the labels are not close, and the weekly schedule is lighter. Saxenda keeps its place for teens and for people whose coverage favors liraglutide. The Mounjaro & Zepbound labels explained guide covers how one molecule carries two brand names.

For liraglutide vs semaglutide vs tirzepatide, or saxenda vs wegovy vs zepbound, two direct trials exist. In STEP 8, weekly semaglutide 2.4 mg produced 15.8% average weight loss at 68 weeks against 6.4% on daily liraglutide 3 mg (JAMA, 2022). In SURMOUNT-5, tirzepatide produced 20.2% at 72 weeks against 13.7% on semaglutide (NEJM, 2025). No trial has tested all three together, or liraglutide against tirzepatide directly.

A licensed clinician reviews your history before either drug is prescribed.